TY - JOUR
TI - Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations
AU - Tausch, E.
AU - Ljungström, V.
AU - Agathangelidis, A.
AU - Zapatka, M.
AU - Scarfò, L.
AU - Jebaraj, B.M.C.
AU - Yosifov, D.Y.
AU - Müller, A.
AU - Munugalavadla, V.
AU - Degenhardt, J.D.
AU - Ghia, P.
AU - Rosenquist, R.
AU - Stilgenbauer, S.
JO - Blood advances
PY - 2022
VL - 139
TODO - 22
SP - 3340-3344
PB - NLM (Medline)
SN - null
TODO - 10.1182/blood.2021014550
TODO - idelalisib;  purine derivative;  quinazolinone derivative, drug resistance;  genetics;  MAPK signaling;  mutation;  tumor cell line;  upregulation, Cell Line, Tumor;  Drug Resistance, Neoplasm;  MAP Kinase Signaling System;  Mutation;  Purines;  Quinazolinones;  Up-Regulation
TODO - null
ER -